NASDAQ:AKRX - Akorn Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.19 -0.08 (-1.87 %) (As of 05/19/2019 04:26 AM ET)Previous Close$4.19Today's Range$4.18 - $4.355052-Week Range$2.64 - $19.65Volume898,389 shsAverage Volume3.36 million shsMarket Capitalization$527.31 millionP/E RatioN/ADividend YieldN/ABeta2.6 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Receive AKRX News and Ratings via Email Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:AKRX Previous Symbol CUSIP00972810 CIK3116 Webwww.akorn.com Phone847-279-6100Debt Debt-to-Equity Ratio2.31 Current Ratio3.26 Quick Ratio2.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$694.02 million Price / Sales0.76 Cash Flow$0.3360 per share Price / Cash Flow12.47 Book Value$2.91 per share Price / Book1.44Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-401,910,000.00 Net Margins-67.38% Return on Equity-13.92% Return on Assets-4.73%Miscellaneous Employees2,191 Outstanding Shares125,850,000Market Cap$527.31 million Next Earnings DateN/A OptionableOptionable Akorn (NASDAQ:AKRX) Frequently Asked Questions What is Akorn's stock symbol? Akorn trades on the NASDAQ under the ticker symbol "AKRX." How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) posted its earnings results on Tuesday, May, 7th. The company reported ($0.10) EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.08. The firm had revenue of $165.90 million for the quarter, compared to the consensus estimate of $153.01 million. Akorn had a negative net margin of 67.38% and a negative return on equity of 13.92%. The firm's revenue for the quarter was down 9.9% compared to the same quarter last year. View Akorn's Earnings History. What guidance has Akorn issued on next quarter's earnings? Akorn updated its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $633.47 million. What price target have analysts set for AKRX? 6 brokerages have issued 1 year price objectives for Akorn's stock. Their predictions range from $4.00 to $11.00. On average, they expect Akorn's stock price to reach $6.80 in the next twelve months. This suggests a possible upside of 62.3% from the stock's current price. View Analyst Price Targets for Akorn. What is the consensus analysts' recommendation for Akorn? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn. Has Akorn been receiving favorable news coverage? Media headlines about AKRX stock have been trending negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akorn earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Akorn's key competitors? Some companies that are related to Akorn include Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR), Nabriva Therapeutics (NBRV), Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK), Pacira Biosciences (PCRX), Tricida (TCDA), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Zogenix (ZGNX) and Zai Lab (ZLAB). What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Alibaba Group (BABA). Who are Akorn's key executives? Akorn's management team includes the folowing people: Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)Dr. Bruce Kutinsky, Consultant (Age 53)Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55) Who are Akorn's major shareholders? Akorn's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.25%), Renaissance Technologies LLC (5.62%), AQR Capital Management LLC (2.61%), Dimensional Fund Advisors LP (2.58%), Goldman Sachs Group Inc. (1.12%) and Northern Trust Corp (1.04%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor, Joseph Bonaccorsi and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn. Which major investors are selling Akorn stock? AKRX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, J. Goldman & Co LP, Assenagon Asset Management S.A., Morgan Stanley, JPMorgan Chase & Co., Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc. and State of Wisconsin Investment Board. View Insider Buying and Selling for Akorn. Which major investors are buying Akorn stock? AKRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, AQR Capital Management LLC, Dimensional Fund Advisors LP, Jacobs Levy Equity Management Inc., Macquarie Group Ltd., Connor Clark & Lunn Investment Management Ltd., Sivik Global Healthcare LLC and Spark Investment Management LLC. Company insiders that have bought Akorn stock in the last two years include Joseph Bonaccorsi and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn. How do I buy shares of Akorn? Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Akorn's stock price today? One share of AKRX stock can currently be purchased for approximately $4.19. How big of a company is Akorn? Akorn has a market capitalization of $527.31 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe. What is Akorn's official website? The official website for Akorn is http://www.akorn.com. How can I contact Akorn? Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected] MarketBeat Community Rating for Akorn (NASDAQ AKRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 489 (Vote Outperform)Underperform Votes: 412 (Vote Underperform)Total Votes: 901MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What type of investment options does a Roth IRA provide? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.